Drug Profile
Research programme: cancer therapeutics - Daiichi Sankyo/Dana-Farber Cancer Institute
Alternative Names: Lung cancer therapeutics - Daiichi SankyoLatest Information Update: 29 Sep 2023
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company; Dana-Farber Cancer Institute
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lung cancer
Most Recent Events
- 29 Sep 2023 Discontinued - Preclinical for Lung cancer in Japan (unspecified route) (Daiichi Sankyo website; September 2023)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Lung-cancer in Japan
- 12 Oct 2016 Preclinical trials in Lung cancer in Japan